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IMPORTANCE Breast cancer is the leading cause of female cancer burden, and its incidence
has increased bymore than 20%worldwide since 2008. Some observational studies have
suggested that theMediterranean diet may reduce the risk of breast cancer.
OBJECTIVE To evaluate the effect of 2 interventions with Mediterranean diet vs the advice to
follow a low-fat diet (control) on breast cancer incidence.
DESIGN, SETTING, AND PARTICIPANTS The PREDIMED study is a 1:1:1 randomized, single-blind,
controlled field trial conducted at primary health care centers in Spain. From 2003 to 2009,
4282 women aged 60 to 80 years and at high cardiovascular disease risk were recruited after
invitation by their primary care physicians.
INTERVENTIONS Participants were randomly allocated to a Mediterranean diet supplemented
with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control
diet (advice to reduce dietary fat).
MAIN OUTCOMES ANDMEASURES Breast cancer incidencewas a prespecified secondary
outcome of the trial for womenwithout a prior history of breast cancer (n = 4152).
RESULTS After a median follow-up of 4.8 years, we identified 35 confirmed incident cases of
breast cancer. Observed rates (per 1000 person-years) were 1.1 for the Mediterranean diet
with extra-virgin olive oil group, 1.8 for the Mediterranean diet with nuts group, and 2.9 for
the control group. Themultivariable-adjusted hazard ratios vs the control group were 0.32
(95% CI, 0.13-0.79) for the Mediterranean diet with extra-virgin olive oil group and 0.59 (95%
CI, 0.26-1.35) for the Mediterranean diet with nuts group. In analyses with yearly cumulative
updated dietary exposures, the hazard ratio for each additional 5% of calories from
extra-virgin olive oil was 0.72 (95% CI, 0.57-0.90).
CONCLUSIONS AND RELEVANCE This is the first randomized trial finding an effect of a
long-term dietary intervention on breast cancer incidence. Our results suggest a beneficial
effect of a Mediterranean diet supplemented with extra-virgin olive oil in the primary
prevention of breast cancer. These results come from a secondary analysis of a previous trial
and are based on few incident cases and, therefore, need to be confirmed in longer-term and
larger studies.
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B reast cancer, the most frequently diagnosed malig-nant tumorandthe leadingcauseofcancerdeathamongwomen,has increasing incidence rates. In2012, 1.7mil-
lion women received a diagnosis of breast cancer. Since the
2008estimates,breast cancer incidencehas increasedbymore
than 20% worldwide, while mortality has increased by 14%.1
In European countries, breast cancer is the most common in-
cident cancer and the first or second (after lung cancer)malig-
nant neoplasm implicated in mortality among women.2
Diet has been extensively studied as amodifiable compo-
nent of lifestyle that could influence breast cancer develop-
ment. Epidemiological evidence on the effect of specific di-
etary factors is still inconsistent, and the only convincing
evidence relates to an increased risk in women with high al-
cohol consumption.3
The inconsistentassociationbetweenfoodsornutrientcon-
sumption and breast cancer risk may be partly due to the fact
that individuals donot consume foodsornutrients in isolation
butmixtures of foodswith different nutrient constituents that
may interact synergistically to influence biological pathways
leading to or protecting from cancer. Thus, assessing diet as a
whole, basedonoverall dietarypatterns, providesmoreuseful
information on the role of diet in breast cancer risk. TheMedi-
terranean dietary pattern has attracted considerable attention
because, historically, breast cancer rates have been lower in
Mediterranean countries than in Northern or Central Euro-
pean countries or theUnited States.4,5 TheMediterraneandiet
(MeDiet) is characterized by an abundance of plant foods, fish,
and especially olive oil.5 In the Lyon Diet Heart Study, partici-
pants allocated to a cardioprotective Mediterranean-type diet
showeda61%lower riskof cancer (all subtypes) than thosepar-
ticipants allocated toa control diet close to the step 1American
HeartAssociationprudentdiet.6Recentprospectivecohortstud-
ieshaveevaluated theassociationbetweenadherence toaMe-
Dietpatternandspecificallybreast cancer risk.7,8However, the
epidemiological evidence is still limited and conflicting.9,10
Moreover, no randomized trial has ever assessed the effect of
theMeDiet on the primary prevention of breast cancer.
To furtherexamine theeffectsof theMeDietonbreast can-
cer risk, we have analyzed the effect of the MeDiet supple-
mented with extra-virgin olive oil (EVOO) or nuts in the ran-
domized interventionof thePREDIMED trial on the incidence
of breast cancer.
Methods
Trial Design
This studywas conducted within the frame of the PREDIMED
(Prevención con Dieta Mediterránea) trial (ISRCTN35739639)
(http://www.predimed.es).11,12Briefly,PREDIMEDisalarge,mul-
ticenter, randomized trialdesigned to test theeffectsof the tra-
ditionalMeDietontheprimarypreventionofcardiovasculardis-
ease (CVD). The protocol (Supplement 2) was approved by the
institutional reviewboards at all study locations. The trial was
stopped in December 1, 2010, after a median follow-up of 4.8
yearsbecauseofevidenceofearlycardiovascularbenefitofboth
MeDiet groups comparedwith the control group.
Participants
Eligible participants for thePREDIMED trialweremenaged55
to 80 years andwomen aged 60 to 80 years free of CVD at en-
rollment, who had either type 2 diabetesmellitus or at least 3
of the followingmajor cardiovascular risk factors: smoking,hy-
pertension, elevated low-density lipoprotein cholesterol level,
low high-density lipoprotein cholesterol level, overweight or
obesity,or familyhistoryofprematurecoronaryheartdisease.11
Study candidates were selected from databases of primary
health care facilities. Of 8367 candidatesmeeting enrollment
criteria, 89% agreed to participate and provided written in-
formed consent.
Randomization, Masking, Interventions, andMeasurements
During theperiodOctober 2003 through June2009, 7447par-
ticipantswere enrolled in the PREDIMED trial, ofwhom4282
were women. Participants were randomly allocated in a 1:1:1
ratio to the 3 intervention groups:MeDiet supplementedwith
EVOO,MeDiet supplementedwithmixednuts, or control diet
(advice to reduce dietary fat). The coordinating center con-
structed a computer-generated randomization table. Alloca-
tion was concealed by opaque, sequentially numbered, and
sealed envelopes and stratified by sex and age. For the pres-
ent study, 1womanwas excludedbecause of a prior diagnosis
of breast cancer and 7 other women were excluded because
of probable (not confirmed as malignant) breast tumors. In-
vestigatorsassessing theoccurrenceofnewbreast cancer cases
were blinded to the intervention.
Participants in the2 interventiongroupsweregivensupple-
mentaryfoodsforfree:EVOO(1L/wkfortheparticipantandtheir
families)ormixednuts (30g/d: 15gwalnuts,7.5ghazelnuts,and
7.5galmonds)accordingto their randomizationgroup.Thepur-
pose of supplementation was both to ensure a high consump-
tion of these key components of the traditional MeDiet and to
promote a better overall adherence to the intervention.
At baseline and quarterly thereafter, dieticians ran indi-
vidual and group sessions, with up to 20 participants, sepa-
rately for each group. In the appropriate individual sessions,
a 14-item dietary screening questionnaire was used to assess
adherence toeitherof theMeDiets, anda9-itemdietaryscreen-
ing questionnaire was used to assess adherence to the con-
trol diet. Theanswers to thequestionnaireswereusedas a tool
to personalize the intervention for eachparticipant and tone-
gotiate changes to upgrade adherence to either theMeDiet or
the control diet.
Participants in thecontrolgroupalsoreceiveddietary train-
ing at the baseline visit and completed the 14-item dietary
screener used to assess baseline adherence to the MeDiet.
Thereafter, during the first 3 years of the trial, they received a
leaflet explaining the low-fat diet on a yearly basis. However,
the realization that themore infrequentvisit schedule and less
intense support for the control group might be limitations of
the trial prompted us to amend the protocol inOctober 2006.
Thereafter, participants assigned to the control diet received
personalized advice and were invited to group sessions with
thesamefrequencyandintensityas those intheMeDietgroups,
with the use of a separate 9-itemdietary screener. During the
study, participants in the control group received gifts of non-
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food items as incentives. Attained changes in diet are shown
in the eTable in Supplement 1.
Energy restriction was not specifically advised, nor was
physical activity promoted in anygroup. The interventiondid
not targetdrugprescriptions; thus, itwas implementedwithin
the regular medical care of the participants.
Outcome
Cases were defined as the first invasive breast cancer (Interna-
tional Classification of Diseases for Oncology codes C50.1-
C50.9). Availability of results from a cytological or histological
examinationwas considered as confirmation. Even though in-
formationonbiologicalparameterswasnot requestedforacase
tobeaccepted,medical recordswerereviewedtoextract this in-
formation. Incidentcases throughDecember1,2010,were iden-
tified from 2 sources: review of all themedical records of each
participant by a panel of physicians (masked to the interven-
tion), both at the primary health care level and at the hospital
level, and death certificates (International Classification of Dis-
eases, NinthRevision, code 174 or International Classification of
Diseases, 10th Revision, code C50). A clinical events committee
blinded to the intervention and the dietary information of par-
ticipants adjudicated all end points using prespecified criteria.
Cancer incidence was defined as a secondary outcome in
theoriginal studyprotocol. Five specific cancer locationswere
always included as relevant outcomes in all interim analyses
and in all reports prepared every year for the Data and Safety
Monitoring Board of the PREDIMED trial: breast cancer, lung
cancer, prostate cancer, colorectal cancer, and gastric cancer.
These results onbreast cancer are the first results for any can-
cer that have been analyzed and submitted for publication in
the PREDIMED trial.
Follow-up ended at the time of diagnosis of an invasive
breast cancer, death, last follow-up contact, or December 1,
2010, whichever occurred first.
Covariates
At baseline and once yearly during follow-up, a validated 14-
itemMeDiet screener,13 a generalmedical questionnaire, a 137-
item validated food frequency questionnaire,14 and the Min-
nesota Leisure-Time Physical Activity Questionnaire15,16 were
administered. Information from the food frequency question-
nairewasusedtocalculate intakeofenergyandnutrients.Other
lifestyle-related variables such as smoking, health conditions,
andsociodemographicvariableswereassessedbya47-itemgen-
eral questionnaire.12 In addition, trained study personnel di-
rectlymeasured weight, height, andwaist circumference.
Sample Size
Sample sizewas estimated for theprimary endpoint, namely,
CVD. It was reassessed in 2008 and set at 7400 participants
with theassumptionof a6-year follow-upandunderlyingCVD
event rates of 8.8% and 6.6% in the control and intervention
groups, respectively.12
Statistical Analysis
Ourmainanalyseswereperformedonan intention-to-treatba-
sis. We used Cox regression models with robust estimates for
the variance to assess the effect of the intervention onmalig-
nant breast cancer incidence. First, we fitted a crude model,
and thenweadjusted for age (3groups:≤60,>60to70, and>70
years), recruitment center, baseline body mass index (calcu-
lated as weight in kilograms divided by height in meters
squared, categorized into quartiles), waist-to-height ratio (di-
chotomous), useofhormone therapy, leisure-timephysical ac-
tivity (categorized into quartiles), total energy intake (catego-
rized into quartiles), alcohol consumption (categorized into
quartiles),ageatmenopause(dichotomous),smokinghabit,dia-
betesmellitus,useof statins, familyhistoryofcancer, andbase-
lineadherenceto theMeDiet (highvs low). Inanancillaryanaly-
sis, we merged both MeDiet groups and assessed their effect
comparedwith the control group.For theprimaryanalysis,we
excluded 7womenwith a non–pathologically confirmed inci-
dent breast cancer. In sensitivity analyses, we included these
women as cases or as noncases. We repeated our analyses af-
ter excluding women who received a diagnosis of malignant
breast cancer during the first year of follow-up and consider-
ing onlymalignant neoplasms positive for estrogen receptors
(ERs). We did subgroup analyses stratifying by age, smoking
status, alcohol intake, prevalent type 2 diabetes, obesity, use
ofhormone therapy, familyhistoryof cancer, andbaseline ad-
herence to the Mediterranean diet. However, the small num-
ber of cases in some of the strata precluded fitting themodels
for someof thesesubgroups.Analyseswere repeatedwithPois-
son regressionmodels with robust estimates for the variance.
Finally,wealso completedaper-protocol analysis inwhichwe
used time-dependentCoxmodels to assess theassociationbe-
tween attained consumption of EVOO during follow-up (cu-
mulative mean across all the available food frequency ques-
tionnaires) and subsequent incidence of breast cancer.
Results
FromOctober2003throughJune2009,4282womenwereran-
domly assigned to 1 of the 3 intervention groups (eFigure in
Supplement 1). Their baseline characteristics are presented in
Table 1. The mean (SD) age of participants was was 67.7 (5.8)
years, and mean (SD) body mass index was 30.4 (4.1). Most
womenunderwentmenopause before 55 years, and less than
3%used hormone therapy. Baseline characteristics werewell
balanced in the 3 groups.
During amedian (SD) follow-up time of 4.8 (1.7) years, we
identified35confirmed incident casesofmalignantbreast can-
cer. Among them, 33 had available information on ER status
and 31were positive. Of 27 caseswith information on proges-
terone receptor status, 21 were positive, and of 21 with infor-
mation on ERBB2 receptors, 12 were positive. For 122 partici-
pants, no information for breast cancer incidence during
follow-up was available.
Women allocated to theMeDiet supplementedwith EVOO
showed a 62% relatively lower risk of malignant breast cancer
than those allocated to the control diet (95% CI, 0.16-0.87)
(Figure 1). Participants in the MeDiet supplemented with nuts
showedanonsignificant risk reduction comparedwithwomen
in the control group (hazard ratio [HR], 0.62 [95% CI, 0.29-
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1.36]).WhenbothMeDietgroupsweremerged together,weob-
serveda51%relativeriskreduction(95%CI,0.25-0.94) (Table2).
Whenwe excludedwomenwho received a diagnosis of malig-
nantbreast cancerduring the first year after enrollment, the re-
sults hardly changed. Similarly, the results did not substan-
tially changeafter includingwomenwithbreast cancerwithno
cytologicalorhistologicalconfirmationeitherascasesorasnon-
cases or when we considered only ER-positive malignant neo-
plasms.Inthestratifiedanalyses,allbut2pointestimatesshowed
an inverseassociationbetweentheMeDietplusEVOOinterven-
tion and the incidence of breast cancer (Table 3).
When we assessed the 3 trial groups together in a per-
protocolanalysis,participantswhoattainedahigherEVOOcon-
sumption during follow-up exhibited the lowest risk (HR for
5thvs 1stquintile,0.18 [95%CI,0.06-0.57]) (Figure2). In these
analyses with yearly cumulative updated dietary exposures,
theHRwas0.72 (95%CI, 0.57-0.90) for each additional 5%of
calories from EVOO.
Table 1. Baseline Characteristics of Female PREDIMED Trial Participants by Intervention Group
Characteristic
MeDiet With EVOO
(n = 1476)
MeDiet With Nuts
(n = 1285)
Control Diet
(n = 1391)
Age, mean (SD), y 67.6 (5.8) 67.4 (5.6) 68.1 (6.0)
Smoking, No. (%)
Never 1276 (86.5) 1123 (87.4) 1216 (87.4)
Former 88 (6.0) 68 (5.3) 78 (5.6)
Current 112 (7.6) 94 (7.3) 97 (7.0)
Body mass index, mean (SD) 30.4 (3.9) 30.2 (4.1) 30.7 (4.2)
Waist to height ratio, mean (SD) 0.64 (0.07) 0.63 (0.07) 0.64 (0.07)
Hypertension,a No. (%) 1269 (86.0) 1114 (86.7) 1197 (86.1)
Type 2 diabetes mellitus,b No. (%) 701 (47.5) 533 (41.5) 618 (44.4)
Dyslipidemia,c No. (%) 1112 (75.3) 1003 (78.1) 1065 (76.6)
Family history of premature coronary heart disease,d
No. (%)
392 (26.6) 328 (25.5) 372 (26.7)
Family history of cancer, No. (%) 807 (54.7) 680 (52.9) 709 (51.0)
Use of hormone therapy, No. (%) 42 (2.9) 34 (2.7) 37 (2.7)
Age at menopause >55 y, No. (%) 102 (6.9) 62 (4.8) 78 (5.6)
Physical activity, mean (SD), METs-min/d 179 (168) 177 (165) 161 (166)
MeDiet adherence score,e mean (SD) 8.7 (1.9) 8.7 (1.9) 8.4 (1.9)
Total energy intake, mean (SD), kcal/d 2163 (568) 2184 (565) 2100 (539)
Alcohol consumption, No. (%)
Abstainers 765 (51.8) 594 (46.2) 760 (54.6)
>0 to <15 g/d 645 (43.7) 642 (50.0) 575 (41.3)
≥15 g/d 66 (4.5) 49 (3.8) 56 (4.0)
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
EVOO, extra-virgin olive oil; MeDiet,
Mediterranean diet; MET, metabolic
equivalent.
a Defined as systolic blood pressure
at least 140mmHg, diastolic blood
pressure at least 90mmHg, or use
of antihypertensive therapy.
bDefined as fasting blood glucose
level at least 126mg/dL (to convert
to millimoles per liter, multiply by
0.0555) on 2 occasions, 2-h plasma
glucose level at least 200mg/dL
after a 75-g oral glucose load, or use
of antidiabetic medication.
c Defined as low-density lipoprotein
cholesterol level greater than 160
mg/dL (to convert to millimoles per
liter, multiply by 0.0259),
high-density lipoprotein cholesterol
level nomore than 40mg/dL in
men or 50mg/dL in women, or use
of lipid-lowering therapy.
dDefined as diagnosis of coronary
heart disease in a male first-degree
relative before the age of 55 y or in a
female first-degree relative before
the age of 65 y.
e On a scale of 0 to 14.
Figure 1. Incidence of Invasive Breast Cancer, According to the Intervention Group
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Hazard ratios were obtained from
Cox regressionmodels. EVOO
indicates extra-virgin olive oil;
HR, hazard ratio; MeDiet,
Mediterranean diet.
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Table 2. Risk of Invasive Breast Cancer According to the Intervention Groupa
Hazard Ratio (95% CI)
Control Diet
(n = 1391)
Mediterranean Diet
With EVOO
(n = 1476)
Mediterranean Diet
With Nuts
(n = 1285)
Both Mediterranean
Diets
(n = 2761)
Cases/person-years 17/5829 8/7031 10/5492 18/12 523
Rate, per 1000 person-years 2.9 1.1 1.8 1.4
Crude rate ratio 1 [Reference] 0.38 (0.16-0.87) 0.62 (0.29-1.36) 0.49 (0.25-0.94)
Multivariable adjusted rate ratiob 1 [Reference] 0.32 (0.13-0.79) 0.59 (0.26-1.35) 0.43 (0.21-0.88)
After excluding women with
follow-up <1 yc
Crude rate ratio 1 [Reference] 0.37 (0.15-0.90) 0.64 (0.28-1.45) 0.48 (0.24-0.98)
Multivariable adjusted rate ratiob 1 [Reference] 0.33 (0.13-0.85) 0.65 (0.27-1.53) 0.46 (0.22-0.96)
After including nonconfirmed cases
as cases
Crude rate ratio 1 [Reference] 0.38 (0.16-0.87) 0.62 (0.29-1.36) 0.49 (0.25-0.94)
Multivariable adjusted rate ratiob 1 [Reference] 0.32 (0.13-0.79) 0.59 (0.26-1.35) 0.43 (0.21-0.88)
After including nonconfirmed cases
as noncases
Crude rate ratio 1 [Reference] 0.38 (0.16-0.87) 0.62 (0.29-1.36) 0.49 (0.25-0.94)
Multivariable adjusted rate ratiob 1 [Reference] 0.32 (0.13-0.79) 0.59 (0.26-1.35) 0.43 (0.21-0.88)
Including only estrogen
receptor–positive malignant
neoplasms
Crude rate ratio 1 [Reference] 0.31 (0.11-0.85) 0.65 (0.27-1.57) 0.46 (0.22-0.98)
Multivariable adjusted rate ratiob 1 [Reference] 0.24 (0.08-0.71) 0.58 (0.23-1.47) 0.38 (0.17-0.86)
Abbreviation: EVOO, extra virgin olive
oil.
a Results obtained from Cox
regressionmodels.
bAdjusted for age (3 groups), study
site (continuous), bodymass index
(quartiles), waist to height ratio
(dichotomous), use of hormone
therapy, leisure-time physical
activity (quartiles), total energy
intake (quartiles), alcohol
consumption (quartiles), age at
menopause (<55 vs55 y), and
baseline adherence to the
Mediterranean diet (high vs low).
c Four cases were excluded: 1 in the
Mediterranean diet with EVOO
group, 1 in theMediterranean diet
with nuts group, and 2 in the control
group.
Table 3. Risk of Invasive Breast Cancer by Intervention Group in Subgroup Analysesa
Variable No.
Cases/
Person-years
Hazard Ratio (95% CI) vs Control Diet
Mediterranean Diet
With EVOO
Mediterranean Diet
With Nuts
Both Mediterranean
Diets
Age
≤67 y 2095 15/9099 0.16 (0.04-0.68) 0.16 (0.04-0.71) 0.16 (0.05-0.50)
>67 y 2057 20/9254 0.56 (0.15-2.03) 1.52 (0.53-4.39) 0.92 (0.34-2.47)
Smoking
Never 3615 31/16 082 0.33 (0.13-0.86) 0.63 (0.27-1.49) 0.46 (0.22-0.96)
Ever 537 4/2271 … … …
Alcohol intake
≤25 g/d 2119 22/9460 0.35 (0.11-1.12) 0.84 (0.32-2.20) 0.54 (0.22-1.29)
>25 g/d 2033 13/8893 0.30 (0.07-1.30) 0.34 (0.08-1.45) 0.32 (0.10-1.06)
Diabetes mellitus
No 2300 16/9967 0.37 (0.10-1.37) 0.49 (0.13-1.81) 0.42 (0.15-1.20)
Yes 1852 19/8385 0.22 (0.05-0.88) 0.61 (0.18-2.00) 0.37 (0.13-1.07)
BMI
<30 1995 17/8809 0.32 (0.09-1.09) 0.27 (0.07-1.16) 0.29 (0.11-0.83)
≥30 2157 18/9543 0.28 (0.07-1.12) 0.99 (0.35-2.81) 0.57 (0.22-1.49)
Use of hormone therapy
No 4039 33/17 905 0.31 (0.12-0.80) 0.64 (0.28-1.46) 0.44 (0.21-0.92)
Yes 113 2/448
Family history of cancerb
No 1702 10/7558 0.19 (0.05-0.70) 0.10 (0.004-2.25) 0.15 (0.03-0.70)
Yes 2196 22/9658 0.37 (0.11-1.21) 0.78 (0.29-2.12) 0.53 (0.22-1.30)
Baseline adherence to the
Mediterranean dietc
Low 1936 21/8398 0.31 (0.10-0.96) 0.39 (0.12-1.26) 0.34 (0.14-0.86)
High 2216 14/9955 0.33 (0.07-1.63) 1.00 (0.25-4.03) 0.62 (0.16-2.33)
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
ellipses, insufficient sample size for
comparison; EVOO, extra-virgin olive
oil.
a Results obtained from Cox
regressionmodels. Adjusted for age
(3 groups), center, bodymass index
(quartiles), waist to height ratio
(dichotomous), use of hormone
therapy, leisure-time physical
activity (quartiles), total energy
intake (quartiles), alcohol
consumption (quartiles), age at
menopause (<55 vs >55 y), and
baseline adherence to the
Mediterranean diet (high vs low).
b Information was not available for
254 women.
c Scored on a scale of 0 to 14 points,
dichotomized into low adherence
(0-8 points) and high adherence
(9-14 points).
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Discussion
In this secondary analysis of the PREDIMED trial, we found a
significant inverse associationbetween consumptionof aMe-
Diet supplemented with EVOO and breast cancer incidence.
A high consumption of EVOO (≥15% of total energy intake)
seems tobe instrumental for obtaining this significant protec-
tion.Anonsignificant risk reductionwasobservedwith theMe-
Diet supplemented with nuts.
The strengths of this study are its randomized design, the
achieved changes in the participants’ dietary habits according
to the intervention,17 little residual confounding with almost
no changes in estimates after adjustment for many potential
confounders, and the thorough and blind revision of medical
information to assess outcomes. The adjudication commit-
tee, whose members were blinded to the intervention group,
assessed the events with specific criteria, dispelling potential
misclassification biases. We also acknowledge some limita-
tions. First, breast cancerwasnot theprimary endpoint of the
PREDIMED trial. Thus, the presentwork is only a prespecified
secondary analysis of a large nutritional intervention trial and
wecannotwarrant thatallwomenhadmammogramsfree from
suggestive findings at baseline. However, the randomization
was able to yield well-balanced and comparable groups, and,
given the large sample size, a balance in other characteristics
canbe safely assumed. Second, thenumberofobservedbreast
cancer cases was small. The potential for missing some inci-
dentbreast cancercases isbasicallynull regardingclinically rel-
evantevents. Inanycase, thispossibilitywill affectonlywomen
lost to follow-up, and most of them belonged to the control
group.Therefore,undetectedcasesofbreastcancerwouldmore
likelyhave increasedeven further the rate in thecontrol group.
Accordingly, our resultswould tend tounderestimate theben-
eficial effect of the intervention. The low rate of breast cancer
among women in the PREDIMED trial should not be surpris-
ing. If the MeDiet is actually protective against breast cancer,
a low incidence is to be expected in a studywith these charac-
teristics, especiallywhenoverall adherence to theMeDietwas
goodalreadyatbaseline.Third,wedonothave informationon
an individual basis on whether and when women in our trial
underwentmammography.Potentially,cancerscouldbemissed
withoutmammograms. However, because of the randomized
design and the large sample size,webelieve thatwecan safely
assumeanevendistributionof subclinical cases in the3groups
under thenullhypothesis.Also,weprioritizedspecificity inour
protocol for case ascertainment and we believe that our pro-
tocol for confirmation of cases ensures a high degree of
specificity.18(p359) Fourth, our participants were white post-
menopausal women at high cardiovascular risk. Thus, our re-
sults may not be generalizable to other age groups or ethnici-
ties. Fifth, information on reproductive factors known to be
associated with breast cancer risk was not available for fur-
ther adjustment.Nevertheless, because of the randomized al-
location of participants, it is not likely that these factors may
have introducedsubstantial confounding.Fifth,our studycan-
notdisentanglewhether theobservedbeneficial effectwas at-
tributablemainly toEVOOorto itsconsumptionwithinthecon-
text of the traditional MeDiet. Sixth, according to the study
event definitions, we collected information on malignant tu-
mors. Thus,wedidnot register noninvasive tumors such as in
situ tumors. Therefore, we cannot include noninvasive cases
in our analyses. Seventh, up to October 2006when the study
protocolwas amended,12 the intervention in the control group
was less intense than in the intervention group. Conse-
quently, some differences in social support, positive expecta-
tions, and empowerment could have existed between the in-
tervention and the control groups. Nevertheless, only 5 cases
of breast cancer had been identified up to that date. In addi-
tion, it seems unlikely that the magnitude of the risk reduc-
tion in breast cancer can be explained only in terms of in-
creased social support.
No prior nutrition intervention trial has addressed the ef-
fectof theMeDiet specificallyonbreast cancer. In theLyonDiet
Heart Study, a randomized trial, a protective effect of a cardio-
protective Mediterranean-type diet against overall cancer in-
cidence was observed, supporting the hypothesis of an anti-
cancer effect of theMeDiet.6 The potential beneficial effect of
theMeDietmay be explained by severalmechanisms,19 for ex-
ample, a reduction inDNAoxidativedamage.20 Specifically for
breast cancer, results fromobservational studieshavebeen in-
consistent.Arecentmeta-analysis21 reportednoassociationbe-
tween adherence to theMeDiet and breast cancer incidence in
Figure 2. Incidence of Breast Cancer, According to Attained Consumption
of Extra-Virgin Olive Oil (EVOO) During Follow-up
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cohortstudies, revealingapooledestimateriskratioof 1.01 (95%
CI, 0.88-1.16), whereas results from case-control studies sug-
gestedan18%riskreduction(95%CI,0.69-0.97).However,most
cohort studies8-10,22 included in this meta-analysis were con-
ductedoutside theMediterraneangeographical areaand it can-
notbeassumed that aproperMeDietwas followedoutside this
region. The EPIC study is the only large cohort study that has
includedcountries fromtheMediterraneanarea.7 In that study,
the HR for postmenopausal women was 0.93 (95% CI, 0.87-
0.99) when comparing high (10-16 points) vs low (0-5 points)
adherence to the MeDiet. If this information (as a prior) were
integratedwithourpresent resultsusinga simpleBayesianap-
proach recommended in epidemiology,18 the posterior rela-
tive riskwouldbe0.92 (95%CI, 0.87-0.98). Thedifferential ef-
fects of the 2 MeDiet interventions on breast cancer may be
attributed to a higher consumption of EVOO among partici-
pants allocated to theMeDiet supplementedwithEVOOas our
ancillaryanalysesshowed(Figure2).ConsumptionofEVOOac-
counted for 22% of total caloric intake in the MeDiet supple-
mentedwithEVOO,whereasnuts represented 10%of the total
calories in the MeDiet supplemented with nuts. The stronger
inverse association with EVOO consumption may also be as-
cribed to its high polyphenol content.
Epidemiological studies on the association between EVOO
consumption and breast cancer incidence are scarce. A meta-
analysis of case-control studies concluded that olive oil con-
sumption, includingnotonlyEVOObutalsoothercommontypes
of oliveoil (with a lower content of bioactivepolyphenols),was
inverselyassociatedwithbreastcancer incidence.23Thesecase-
control studies have been conducted in Mediterranean coun-
tries, and they consistently found an inverse association be-
tweenoliveoilconsumptionandbreastcancerrisk.This finding,
however,wasnot replicated in theEPIC cohort.24Nonetheless,
it is noteworthy that none of these studies differentiated be-
tweentypesofoliveoil.Severalbiologicalmechanismscouldex-
plaintheputativeanticarcinogenicpropertiesofEVOO.All types
of olive oil provide a high supply ofmonounsaturated fatty ac-
ids, mainly oleic acid, as well as squalene, whereas EVOO also
containsvariousbiologicallyactivecompounds,suchasthepoly-
phenols oleocanthal, oleuropein, hydroxytyrosol, and lignans.
In vitro studies have suggested that oleic acidhas an antiprolif-
erativeeffectbyaffectingtheexpressionofhumanoncogenes.25
Thehydrocarbon squalenehas been reported to exert a benefi-
cial effect on intracellular oxidative stress and DNA oxidative
damageinmammaryepithelialcells.26Oliveoilpolyphenolsmay
haveapotential role inbreast cancerprevention.27Oleocanthal
has been associated with inhibition of tumor growth and pro-
liferation, migration, and invasiveness of breast cancer cells in
in vitro or in vivo breast cancermodels.28 Oleuropein has been
associated with increased apoptosis of cultured breast cancer
cells throughdifferentpathways.29,30Also, hydroxytyrosol has
beenreported to reduce intracellular reactiveoxygenspecies in
humanbreastepithelialcellsandtopreventoxidativeDNAdam-
age inbothhumanbreastepithelial cells andhumanbreast can-
cer cells.31 Lignansarephytoestrogenswhoseconsumptionhas
beenassociatedwitha lower riskof breast cancer inpostmeno-
pausal women.32
In thePREDIMEDtrial,participants in thecontrolgroupdid
not reduce their total fat intake substantially—albeit their satu-
rated fat intake stayed less than 10% during follow-up—even
though they were advised to follow a low-fat diet. This result
can be ascribed to the rooted tradition of adherence to theMe-
Diet, particularly among older people. On the other hand, sev-
eral prospective studies have suggested that higher fat in-
takes,especiallyanimal fat,maybeassociatedwithahigher risk
of breast cancer.33-36 Moreover, in the Women’s Health Initia-
tive study, total fat consumptionwas associatedwith a higher
risk of breast cancer.37 Also, in the Women’s Health Initiative
study, women who reported the highest levels of fat intake at
baseline and therefore may have achieved the greatest reduc-
tion in fat intake showed a significantly lower risk of breast
cancer.38 Among womenwith early-stage breast cancer in the
Women's Intervention Nutrition Study, lower fat intakes were
associated with lower estrogen-negative breast cancer
recurrence.39 Taking all this evidence into account, greater re-
ductions in the incidence of breast cancer could have been ob-
served in the control group had these women followed a truly
low-fat diet.
Conclusions
The results of the PREDIMED trial suggest a beneficial effect
of aMeDiet supplementedwith EVOO in the primary preven-
tionof breast cancer. Preventive strategies represent themost
sensible approach against cancer. The intervention paradigm
implemented in the PREDIMED trial provides a useful sce-
nario for breast cancer prevention because it is conducted in
primary health care centers and also offers beneficial effects
on a wide variety of health outcomes.40 Nevertheless, these
results need confirmation by long-term studies with a higher
number of incident cases.
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Editor's Note
Can Diet Prevent Breast Cancer?
Mitchell H. Katz, MD
There is a largebodyofobservationaldataon theeffect ofdiet
on incidenceof cancer.Theproblemis thatobservational stud-
ies of diet are prone to confounding because peoplewho eat a
particular type of diet are likely to be different in other ways
from their comparators. For example, people who eat lots of
fruits and vegetables are likely to engage in other health-
promotingbehaviorscomparedwiththosewhoeatadietheavy
in meat, animal fat, or pro-
cessed foods. Although so-
phisticated multivariable
modeling, combined with the currently popular propensity
scores, can attempt to isolate the impact of a single effect, sta-
tistical adjustment of known confounders for observational
data is imperfect, and adjustment for unknown or unmea-
sured confounders, impossible.
When theEditors read the studybyToledoet al1 on the im-
pact of a Mediterranean diet on the incidence of breast can-
cer,wewere immediately impressed that it was a randomized
clinical trial of diet. Using this high-quality structure, they ob-
served significantdecreases in cancer incidence in thewomen
randomized to theMediterraneandiet supplementedwith ex-
tra-virgin olive oil compared with the control group.
Of course, no study is perfect. This one has a small num-
ber of outcomes (only 35 incident cases of breast cancer), the
women were not all screened for breast cancer with mam-
mography, they were not blinded to the type of diet they
were receiving, and all were white, postmenopausal, and at
high risk for cardiovascular disease. Still, consumption of a
Mediterranean diet, which is based on plant foods, fish, and
extra-virgin olive oil, is known to reduce the risk of cardio-
vascular disease and is safe. It may also prevent breast can-
cer. We hope to see more emphasis on Mediterranean diet to
reduce cancer and cardiovascular disease and improve health
and well-being.
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